123 related articles for article (PubMed ID: 38470512)
1. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.
Brodtkorb TH; Knight C; Kamgar F; Teitsson S; Kurt M; Patel MY; Poretta T; Mamtani R; Palmer S
J Med Econ; 2024; 27(1):543-553. PubMed ID: 38470512
[TBL] [Abstract][Full Text] [Related]
2. Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo.
Teitsson S; Brodtkorb TH; Kurt M; Patel MY; Poretta T; Knight C; Kamgar F; Palmer S
J Med Econ; 2024; 27(1):473-481. PubMed ID: 38385621
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.
McCrea C; Johal S; Yang S; Doan J
Exp Hematol Oncol; 2018; 7():4. PubMed ID: 29456880
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
Sarfaty M; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Eur Urol; 2018 Apr; 73(4):628-634. PubMed ID: 28807351
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Bajorin DF; Witjes JA; Gschwend JE; Schenker M; Valderrama BP; Tomita Y; Bamias A; Lebret T; Shariat SF; Park SH; Ye D; Agerbaek M; Enting D; McDermott R; Gajate P; Peer A; Milowsky MI; Nosov A; Neif Antonio J; Tupikowski K; Toms L; Fischer BS; Qureshi A; Collette S; Unsal-Kacmaz K; Broughton E; Zardavas D; Koon HB; Galsky MD
N Engl J Med; 2021 Jun; 384(22):2102-2114. PubMed ID: 34077643
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Tringale KR; Carroll KT; Zakeri K; Sacco AG; Barnachea L; Murphy JD
J Natl Cancer Inst; 2018 May; 110(5):479-485. PubMed ID: 29126314
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
13. Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
Witjes JA; Galsky MD; Gschwend JE; Broughton E; Braverman J; Nasroulah F; Maira-Arce M; Ye X; Shi L; Guo S; Hamilton M; Bajorin DF
Eur Urol Oncol; 2022 Oct; 5(5):553-563. PubMed ID: 35288066
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
[TBL] [Abstract][Full Text] [Related]
15. A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer.
Roth JA; Yuan Y; Othus M; Danese M; Wagner S; Penrod JR; Ramsey SD
J Med Econ; 2021; 24(1):79-86. PubMed ID: 33334176
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price.
Kim H; Goodall S; Liew D
J Med Econ; 2021; 24(1):893-899. PubMed ID: 34259119
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
Smare C; Dave K; Juarez-Garcia A; Abraham P; Penrod JR; Camidge DR; Yuan Y
J Med Econ; 2021; 24(1):1124-1133. PubMed ID: 34465261
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]